FR2830198A1 - Compositions containing Ravensara aromatica essential oil and one or more other essential oils for treatment of viral, fungal, and parasitic infections, cystic fibrosis, AIDS, and certain tumors - Google Patents

Compositions containing Ravensara aromatica essential oil and one or more other essential oils for treatment of viral, fungal, and parasitic infections, cystic fibrosis, AIDS, and certain tumors Download PDF

Info

Publication number
FR2830198A1
FR2830198A1 FR0112543A FR0112543A FR2830198A1 FR 2830198 A1 FR2830198 A1 FR 2830198A1 FR 0112543 A FR0112543 A FR 0112543A FR 0112543 A FR0112543 A FR 0112543A FR 2830198 A1 FR2830198 A1 FR 2830198A1
Authority
FR
France
Prior art keywords
sep
aromatica
pharmaceutical compositions
essential
ravensara
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0112543A
Other languages
French (fr)
Other versions
FR2830198B1 (en
Inventor
Jean Pierre Willem
Original Assignee
Jean Pierre Willem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jean Pierre Willem filed Critical Jean Pierre Willem
Priority to FR0112543A priority Critical patent/FR2830198B1/en
Publication of FR2830198A1 publication Critical patent/FR2830198A1/en
Application granted granted Critical
Publication of FR2830198B1 publication Critical patent/FR2830198B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/27Asclepiadaceae (Milkweed family), e.g. hoya
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/45Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/54Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/61Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Abstract

Compositions containing the essential oil of Ravensara aromatica (Agathophyllum aromatica) together with other essential oils. Compositions containing the essential oil of Ravensara aromatica (Agathophyllum aromatica) together with other essential oils selected from those obtained from Origanum compactum, Melaleuca quinquenervia, Helichrysum italicum, Laurus nobilis, Trachyspermum ammi, Eugenia aromatica, Eugenia caryophyllata, Inula graveolens, Cymbopogon martinii, Rosmarinus officinale, Eucalyptus radiata, Ocimum basilicum, Lavandula spica, Thymus officinalis, Cistus ladanifer, Aniba rosaedora, Melaleuca alternifolia, Cinnanomumcassia, Cinnanomum aromaticum, Ledum groenlandicum, Calatropis procera, and Cajanus catjan, in a carrier, excipient or diluent appropriate for therapeutic use.

Description

<Desc/Clms Page number 1> <Desc / Clms Page number 1>

COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES HUILES
ESSENTIELLES ET LEURS UTILISATIONS La présente invention se rapporte à l'utilisation de plantes ou de parties de plantes, pour la réalisation de compositions pharmaceutiques.
PHARMACEUTICAL COMPOSITIONS COMPRISING OILS
The present invention relates to the use of plants or parts of plants for producing pharmaceutical compositions.

L'invention concerne plus particulièrement des compositions pharmaceutiques renfermant principalement de l'huile essentielle de Ravensara aromatica (Agathophyllum aromatica) associée à d'autres extraits de plantes. The invention more particularly relates to pharmaceutical compositions containing mainly Ravensara aromatica essential oil (Agathophyllum aromatica) combined with other plant extracts.

Elle a spécifiquement pour objet des compositions pharmaceutiques caractérisées en ce qu'elles contiennent principalement de l'huile essentielle de Ravensara aromatica associée à d'autres huiles essentielles choisies parmi l'Origan (Origanum compactum), le Niaouli (Melaleuca quinquenervia), l'Hélichryse (Helichrysum italicum), le Laurier noble (Laurus nobilis), l'Ajowan (Trachyspermum ammi), le Giroflier (Eugenia aromatica et Eugenia caryophyllata), l'inule odorante (Inula graveolens), le Palmarosa (Cymbopogon martinii), le Romarin (Rosmarinus officinalis), l'Eucalyptus radié (Eucalyptus radiata), le Basilic (Ocimum basilicum), la Lavande aspic (Lavandula spica), les Thym (Thymus officinalis et autres), la Ciste

Figure img00010001

ladanifère (Cistus ladanifer), le bois de rose (Aniba rosaedora), le Tea Tree (Melaleuca alternifolia), la Cannelle de Chine (Cinnanomum cassia et Cinnanomum aromaticum), le Ledon du groënland (Ledum groenlandicum), la Pomme de Sodome (Calotropis procera) et le Pois d'Angole (Cajanus cajan) dans un excipient, un véhicule ou un diluant approprié pour l'usage thérapeutique. It relates specifically to pharmaceutical compositions characterized in that they contain mainly the essential oil of Ravensara aromatica combined with other essential oils selected from the oregano (Origanum compactum), the Niaouli (Melaleuca quinquenervia), the Helichrysum (Helichrysum italicum), the noble laurel (Laurus nobilis), the Ajowan (Trachyspermum ammi), the Giraffe (Eugenia aromatica and Eugenia caryophyllata), the fragrant inula (Inula graveolens), the Palmarosa (Cymbopogon martinii), the Rosemary (Rosmarinus officinalis), Eucalyptus radish (Eucalyptus radiata), Basil (Ocimum basilicum), Lavender aspic (Lavandula spica), Thyme (Thymus officinalis and others), Cistus
Figure img00010001

ladanifer (Cistus ladanifer), rosewood (Aniba rosaedora), Tea Tree (Melaleuca alternifolia), Chinese cinnamon (Cinnanomum cassia and Cinnanomum aromaticum), Greenland Ledon (Ledum groenlandicum), Sodom apple (Calotropis procera) and pigeon pea (Cajanus cajan) in a carrier, vehicle or diluent suitable for therapeutic use.

Les huiles essentielles peuvent également être utilisées telles quelles. Essential oils can also be used as is.

Les compositions pharmaceutiques selon l'invention peuvent contenir en outre un extrait de Poivrier (Piper nigrum ou Piper longum) ou de la pipérine qui renforce sensiblement les effets des principes actifs contenus dans les huiles essentielles des plantes utilisées dans la présente invention. The pharmaceutical compositions according to the invention may also contain a pepper extract (Piper nigrum or Piper longum) or piperine which substantially enhances the effects of the active principles contained in the essential oils of the plants used in the present invention.

<Desc/Clms Page number 2> <Desc / Clms Page number 2>

Les compositions pharmaceutiques selon l'invention s'adressent plus particulièrement au traitement des affections virales, et/ou infectieuses, et/ou fongiques, et/ou parasitaires, des maladies comme la mucoviscidose, des immunodéficiences telles que le SIDA et le traitement de certaines tumeurs. The pharmaceutical compositions according to the invention are more particularly intended for the treatment of viral and / or infectious and / or fungal and / or parasitic diseases, diseases such as cystic fibrosis, immunodeficiencies such as AIDS and the treatment of certain diseases. you die.

Les propriétés anti-infectieuses et antivirales de Ravensara aromatica sont connues et utilisées en aromathérapie. Les rameaux feuillus de Ravensara aromatica sont utilisés traditionnellement en infusion comme stomachique et carminatif et en sirop comme expectorant. The anti-infectious and antiviral properties of Ravensara aromatica are known and used in aromatherapy. The leafy twigs of Ravensara aromatica are traditionally used in infusion as stomachic and carminative and in syrup as expectorant.

Les jeunes rameaux feuillus fournissent l'huile essentielle qui possède des propriétés neurotoniques, immunostimulantes, antivirales, anti infectieuses et décontractantes. The young hardwood twigs provide the essential oil which has neurotonic, immunostimulant, antiviral, anti-infectious and relaxing properties.

De même les huiles essentielles des autres plantes utilisées dans les compositions pharmaceutiques de la présente invention sont connues pour leurs propriétés fongicides (Ajowan, Lavande aspic, Clou de Girofle, Origan), antivirales (Eucalyptus), parasiticide (Ajowan, Cannelle de Chine) et immunostimulantes (Clou de Girofle, Eucalyptus, Origan). Similarly, the essential oils of the other plants used in the pharmaceutical compositions of the present invention are known for their fungicidal properties (Ajowan, Lavande aspic, Clove, Oregano), antiviral (Eucalyptus), parasiticide (Ajowan, Cinnamon from China) and immunostimulant (Clove, Eucalyptus, Oregano).

Par exemple, le Niaouli est réputé comme ayant des propriétés anti-infectieuses, anti-fongiques et antivirales. L'huile essentielle de cette plante, riche en oxydes monoterpéniques (45 à 60% de 1-8 cinéole), en monoterpène (10 % d'a-pinène, 5 à 9 % de limonène), en sesquiterpénols (2 à 10% de viridiflorol) est utilisée pour traiter les infections des voies respiratoires, la grippe et l'herpès. For example, Niaouli is reputed to have anti-infective, anti-fungal and antiviral properties. The essential oil of this plant, rich in monoterpene oxides (45 to 60% of 1-8 cineole), in monoterpene (10% of a-pinene, 5 to 9% of limonene), in sesquiterpenols (2 to 10% viridiflorol) is used to treat infections of the respiratory tract, influenza and herpes.

L'association d'Eucalyptus radié, d'Hélichryse, d'Inule odorante, de Laurier noble, de Lavande aspic, de Romarin, de Niaouli et de Ravensara aromatica forme une composition pharmaceutique idéale pour le traitement de la mucoviscidose. The combination of Eucalyptus radish, Helichryse, Inula fragrant, Laurel noble, Lavender aspic, Rosemary, Niaouli and Ravensara aromatica forms an ideal pharmaceutical composition for the treatment of cystic fibrosis.

L'association d'Ajowa, de Cannelle de Chine, de Clou de Girofle, de Laurier noble,, de Lavande aspic, d'Origan et de Ravensara forme une composition pharmaceutique idéale pour le traitement des infections fongiques. The combination of Ajowa, Chinese Cinnamon, Clove, Laurel, Lavender Aspic, Oregano and Ravensara forms an ideal pharmaceutical composition for the treatment of fungal infections.

<Desc/Clms Page number 3> <Desc / Clms Page number 3>

L'association d'Ajowan, d'écorce de Cannelle de Chine, de Clou de Girofle, de Tea Tree et de Thym thymol forme une composition pharmaceutique idéale pour le traitement des infections parasitaires. The combination of Ajowan, Chinese Cinnamon Bark, Clove, Tea Tree and Thym Thymol forms an ideal pharmaceutical composition for the treatment of parasitic infections.

L'association de Ravensara, d'extrait de graines de Pois d'Angole et de Pomme de Sodome forme une composition pharmaceutique idéale pour le traitement de la drépanocytose. The combination of Ravensara, pea seed extract and Sodom apple forms an ideal pharmaceutical composition for the treatment of sickle cell disease.

L'association d'Ajowan, de bois de Rose, de Cannelle de Chine, de Ciste ladanifère, d'Eucalyptus radié, de Clou de Girofle, de Lavande aspic, d'Origan, de Tea Tree, de Thym thymol, de Thym thujanol, de Ravensara et de Palmarosa forme une composition pharmaceutique idéale pour le traitement de l'immunodéficience humaine (SIDA). The combination of Ajowan, Rosewood, Chinese Cinnamon, Rockrose Cistus, Eucalyptus Radish, Clove, Lavender Aspic, Oregano, Tea Tree, Thym Thymol, Thyme Thujanol , Ravensara and Palmarosa form an ideal pharmaceutical composition for the treatment of human immunodeficiency (AIDS).

L'association de Ravensara, de Ledon du groenland, de Basilic exotique, de Thym thujanol et de Romarin forme une composition pharmaceutique idéale pour le traitement des hépatites. The combination of Ravensara, Ledon Greenland, Exotic Basil, Thyme Thyuanol and Rosemary forms an ideal pharmaceutical composition for the treatment of hepatitis.

On peut également citer à cet égard la demande de brevet FR 2 709 964 qui a pour objet l'utilisation de Ravensara aromatica en association avec certaines variétés de Lavande, de Niaouli, de Basilic, avec du sulfate de zinc, de l'oxyde de zinc et du sulfate de cuivre, pour le traitement de l'herpès et de l'immunodéficience humaine (SIDA). One can also cite in this regard the patent application FR 2 709 964 which relates to the use of Ravensara aromatica in combination with certain varieties of Lavender, Niaouli, Basil, with zinc sulfate, the oxide of zinc and copper sulfate, for the treatment of herpes and human immunodeficiency (AIDS).

Les compositions pharmaceutiques selon la présente invention sont nettement plus actives. The pharmaceutical compositions according to the present invention are significantly more active.

Les compositions pharmaceutiques de la présente invention contiennent de 30% à 80% d'huile essentielle de Ravensara aromatica qui est riche en 1-8 cinéole, un oxyde monoterpénique dont les propriétés antivirales, immunostimulantes et anti bactériennes sont déjà connues. The pharmaceutical compositions of the present invention contain from 30% to 80% of Ravensara aromatica essential oil which is rich in 1-8 cineole, a monoterpene oxide whose antiviral, immunostimulant and anti-bacterial properties are already known.

L'intérêt de la présente invention est l'obtention de compositions pharmaceutiques contenant principalement de l'huile essentielle de Ravensara aromatica, en association avec d'autres extraits de plantes pour obtenir une potentialisation des The advantage of the present invention is the production of pharmaceutical compositions containing mainly the essential oil of Ravensara aromatica, in combination with other plant extracts to obtain a potentiation of

<Desc/Clms Page number 4><Desc / Clms Page number 4>

effets antiviraux, anti infectieux, fongicides, parasiticides, immunostimulants et/ou anticancéreux.  antiviral, anti-infectious, fungicidal, parasiticidal, immunostimulant and / or anticancer effects.

Les compositions de la présente invention peuvent être appliquées localement notamment sous la forme de mélanges d'huiles essentielles brutes ou bien d'émulsions H/E ou E/H, de gels, de pommades, d'huiles, de laits, de liposomes. Les compositions pharmaceutiques peuvent également être administrées par voie orale, per-cutanéee, ou rectale, selon les cas, sous la forme de capsules molles, de gélules, de biogranules (malt), de suppositoire, de solutions ou d'émulsions huileuses. The compositions of the present invention may be applied locally, especially in the form of mixtures of crude essential oils or of O / W or W / O emulsions, gels, ointments, oils, milks or liposomes. The pharmaceutical compositions can also be administered orally, percutaneously or rectally, as appropriate, in the form of soft capsules, capsules, biogranules (malt), suppository, solutions or oily emulsions.

De façon avantageuse, les compositions pharmaceutiques sont présentées sous la forme de mélange d'huiles essentielles dispersée dans une huile pénétrante et peuvent être utilisées en massage sur le thorax, les poignets et la nuque, à raison de 8 à 12 gouttes, trois fois par jour. Advantageously, the pharmaceutical compositions are presented in the form of a mixture of essential oils dispersed in a penetrating oil and can be used in massage on the thorax, wrists and nape, at a rate of 8 to 12 drops, three times per day. day.

Parmi les huiles pénétrantes ou pourra citer l'huile d'amande douce, l'huile de noisette ou l'huile de bourrache. Penetrating oils include sweet almond oil, hazelnut oil or borage oil.

Des exemples non limitatifs de compositions pharmaceutiques selon l'invention sont présentés ci-dessous : - Composition pour application topique antivirale (SIDA)

Figure img00040001
Nonlimiting examples of pharmaceutical compositions according to the invention are presented below: - Composition for antiviral topical application (AIDS)
Figure img00040001

<tb>
<tb> Huile <SEP> essentielle <SEP> de <SEP> Ravensara <SEP> aromatica <SEP> 30%
<tb> Huile <SEP> essentielle <SEP> d'Origan <SEP> compactum <SEP> 10%
<tb> Huile <SEP> essentielle <SEP> de <SEP> Niaouli <SEP> 6%
<tb> Huile <SEP> essentielle <SEP> de <SEP> Laurier <SEP> noble <SEP> 8%
<tb> Huile <SEP> essentielle <SEP> d'Eucalyptus <SEP> radiata <SEP> 6%
<tb> Huile <SEP> d'Amande <SEP> douce <SEP> 40%
<tb>
- Composition orale pour usage anti-cancéreux :
<Tb>
<tb> Oil <SEP> essential <SEP> of <SEP> Ravensara <SEP> aromatica <SEP> 30%
<tb> Oil <SEP> essential <SEP> Oregano <SEP> compactum <SEP> 10%
<tb> Oil <SEP> essential <SEP> of <SEP> Niaouli <SEP> 6%
<tb> Oil <SEP> essential <SEP> of <SEP> Laurel <SEP> noble <SEP> 8%
<tb> Oil <SEP> essential <SEP> of Eucalyptus <SEP> radiata <SEP> 6%
<tb> Oil <SEP> Almond <SEP> Sweet <SEP> 40%
<Tb>
- Oral composition for anti-cancer use:

<Desc/Clms Page number 5> <Desc / Clms Page number 5>

Figure img00050001
Figure img00050001

<tb>
<tb> Huile <SEP> essentielle <SEP> de <SEP> Ravensara <SEP> aromatica <SEP> 60%
<tb> Huile <SEP> essentielle <SEP> de <SEP> Ledum <SEP> groenlandicum <SEP> 10%
<tb> Huile <SEP> essentielle <SEP> d'Helichrysum <SEP> italicum <SEP> 10%
<tb> Poloxamer <SEP> 188 <SEP> 2%
<tb> Véhicule <SEP> aqueux <SEP> qsp <SEP> 100%
<tb>
Les compositions selon l'invention peuvent encore être formées d'une émulsion buvable répartie en ampoules.

Figure img00050002
<Tb>
<tb> Oil <SEP> essential <SEP> from <SEP> Ravensara <SEP> aromatica <SEP> 60%
<tb> Oil <SEP> essential <SEP> of <SEP> Ledum <SEP> groenlandicum <SEP> 10%
<tb> Oil <SEP> essential <SEP> of Helichrysum <SEP> italicum <SEP> 10%
<tb> Poloxamer <SEP> 188 <SEP> 2%
<tb> Vehicle <SEP> aqueous <SEP> qsp <SEP> 100%
<Tb>
The compositions according to the invention may also be formed of an oral emulsion distributed in ampoules.
Figure img00050002

<tb>
<tb>
<Tb>
<Tb>

- <SEP> Suspension <SEP> buvable <SEP> antivirale
<tb> Huile <SEP> essentielle <SEP> de <SEP> Ravensara <SEP> aromatica <SEP> 40%
<tb> Huile <SEP> essentielle <SEP> d'Origan <SEP> compactum <SEP> 4%
<tb> Huile <SEP> essentielle <SEP> de <SEP> Lavande <SEP> aspic <SEP> 8%
<tb> Hydroxy-éthyl-cellulose <SEP> 2%
<tb> Hydroxy-propyl-méthyl-cell <SEP> ulose <SEP> 4%
<tb> Tween <SEP> 80 <SEP> 0,2%
<tb> Eau <SEP> purifiée <SEP> qsp <SEP> 100%
<tb>
- Capsules molles On dissout dans 100ml d'huile de germe de blé, un mélange de 60% d'huile essentielle de Ravensara aromatica, 20% d'huile essentielle d'Origan, et de 20% d'huile essentielle de Basilic. On ajoute au mélange 0,1 g de pipérine et on homogénéise le mélange.
- <SEP> Suspension <SEP> drinkable <SEP> antiviral
<tb> Oil <SEP> essential <SEP> from <SEP> Ravensara <SEP> aromatica <SEP> 40%
<tb> Oil <SEP> essential <SEP> Oregano <SEP> compactum <SEP> 4%
<tb> Oil <SEP> essential <SEP> of <SEP> Lavender <SEP> aspic <SEP> 8%
<tb> Hydroxyethylcellulose <SEP> 2%
<tb> Hydroxy-propyl-methyl-cell <SEP> ulose <SEP> 4%
<tb> Tween <SEP> 80 <SEP> 0.2%
<tb> Water <SEP> purified <SEP> qsp <SEP> 100%
<Tb>
- Soft capsules In 100ml of wheat germ oil, a mixture of 60% of Ravensara aromatica essential oil, 20% of Oregano essential oil and 20% of Basil essential oil is dissolved. 0.1 g of piperine is added to the mixture and the mixture is homogenized.

Le mélange est ensuite réparti en capsules de gélatine contenant chacune 0,2g de la solution huileuse.The mixture is then distributed into gelatin capsules each containing 0.2 g of the oily solution.

Claims (6)

(Thymus officinalis et autres), la Ciste ladanifère (Cistus ladanifer), le bois de rose (Aniba rosaedora), le Tea Tree (Melaleuca alternifolia), la Cannelle de Chine ( Cinnanomum cassia et Cinnanomum aromaticum), le Ledon du groënland (Ledum groenlandicum), la Pomme de Sodome (Calotropis procera) et le Pois d'Angole (Cajanus cajan) dans un excipient, un véhicule ou un diluant approprié pour l'usage thérapeutique.  (Thymus officinalis and others), Ladaniferous Cistus (Cistus ladanifer), Rosewood (Aniba rosaedora), Tea Tree (Melaleuca alternifolia), Chinese Cinnamon (Cinnanomum cassia and Cinnanomum aromaticum), Ledon of Greenland (Ledum groenlandicum), Sodom apple (Calotropis procera) and Pigeon pea (Cajanus cajan) in a carrier, vehicle or diluent suitable for therapeutic use.
Figure img00060001
Figure img00060001
REVENDICATIONS 1. Compositions pharmaceutiques caractérisées en ce qu'elles contiennent principalement l'huile essentielle de Ravensara aromatica associée à d'autres huiles essentielles choisies parmi l'Origan (Origanum compactum), le Niaouli (Melaleuca quinquenervia), l'Hélichryse (Helichrysum italicum), le Laurier noble (Laurus nobilis), l'Ajowan (Trachyspermum ammi), le Giroflier (Eugenia aromatica et Eugenia caryophyllata), l'Inule odorante (Inula graveolens), le Palmarosa (Cymbopogon martinii), le Romarin (Rosmarinus officinalis), l'Eucalyptus radié (Eucalyptus radiata), le Basilic (Ocimum basilicum), la Lavande aspic (Lavandula spica), les Thym  1. Pharmaceutical compositions characterized in that they contain mainly the essential oil of Ravensara aromatica combined with other essential oils selected from oregano (Origanum compactum), Niaouli (Melaleuca quinquenervia), Helichrysum (Helichrysum italicum) ), Laurel (Laurus nobilis), Ajowan (Trachyspermum ammi), Giraffe (Eugenia aromatica and Eugenia caryophyllata), Inula fragrant (Inula graveolens), Palmarosa (Cymbopogon martinii), Rosemary (Rosmarinus officinalis) , Eucalyptus radiata (Eucalyptus radiata), Basil (Ocimum basilicum), Lavender aspic (Lavandula spica), Thyme
2. Compositions pharmaceutiques selon la revendication 1, caractérisées en ce qu'elles contiennent de 30% à 80% d'huile essentielle de Ravensara aromatica. 2. Pharmaceutical compositions according to claim 1, characterized in that they contain from 30% to 80% of essential oil of Ravensara aromatica. 3. Compositions pharmaceutiques selon la revendication 1, caractérisées en ce que l'excipient ou le véhicule est un de ceux qui conviennent pour être appliquées localement sous forme d'émulsions H/E ou E/H, de gels, de pommades, d'huiles, de laits, de liposomes. 3. Pharmaceutical compositions according to claim 1, characterized in that the excipient or the vehicle is one of those which are suitable for being applied locally in the form of O / W or W / O emulsions, gels, ointments, oils, milks, liposomes. 4. Compositions pharmaceutiques selon la revendication 1, caractérisées en ce que l'excipient ou le véhicule est un de ceux qui conviennent pour être pour être administrées par voie orale, per-cutanéee, ou rectale, notamment sous la forme de capsules molles, de gélules, de biogranules (malt), de suppositoire, de solutions ou d'émulsions huileuses. 4. Pharmaceutical compositions according to claim 1, characterized in that the excipient or the vehicle is one of those which are suitable for being administered orally, percutaneously, or rectally, in particular in the form of soft capsules, capsules, biogranules (malt), suppository, solutions or oily emulsions. <Desc/Clms Page number 7> <Desc / Clms Page number 7> 5. Compositions pharmaceutiques selon la revendication 1, caractérisées en ce qu'elles conviennent pour être appliquées sous la forme de mélanges d'huiles essentielles brutes. 5. Pharmaceutical compositions according to claim 1, characterized in that they are suitable for application in the form of mixtures of crude essential oils. 6. Utilisation des compositions pharmaceutiques selon l'une des revendications 1 à 5 pour le traitement des affections virales, et/ou infectieuses, et/ou fongiques, et/ou parasitaires, des maladies comme la mucoviscidose, des immunodéficiences telles que le SIDA et le traitement de certaines tumeurs.6. Use of the pharmaceutical compositions according to one of claims 1 to 5 for the treatment of viral diseases, and / or infectious, and / or fungal, and / or parasitic, diseases such as cystic fibrosis, immunodeficiencies such as AIDS and the treatment of certain tumors.
FR0112543A 2001-09-28 2001-09-28 PHARMACEUTICAL COMPOSITIONS COMPRISING ESSENTIAL OILS AND USES THEREOF Expired - Fee Related FR2830198B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0112543A FR2830198B1 (en) 2001-09-28 2001-09-28 PHARMACEUTICAL COMPOSITIONS COMPRISING ESSENTIAL OILS AND USES THEREOF

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0112543A FR2830198B1 (en) 2001-09-28 2001-09-28 PHARMACEUTICAL COMPOSITIONS COMPRISING ESSENTIAL OILS AND USES THEREOF

Publications (2)

Publication Number Publication Date
FR2830198A1 true FR2830198A1 (en) 2003-04-04
FR2830198B1 FR2830198B1 (en) 2004-10-15

Family

ID=8867745

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0112543A Expired - Fee Related FR2830198B1 (en) 2001-09-28 2001-09-28 PHARMACEUTICAL COMPOSITIONS COMPRISING ESSENTIAL OILS AND USES THEREOF

Country Status (1)

Country Link
FR (1) FR2830198B1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006087039A1 (en) * 2005-02-17 2006-08-24 Propharex Sa Broad spectrum anti viral herbal composition
WO2007116062A1 (en) * 2006-04-11 2007-10-18 Swiss Caps Rechte Und Lizenzen Ag Capsules containing plant preparations
ES2340352A1 (en) * 2008-06-06 2010-06-01 Pedro Enrique Alonso Hernandez Unguent or liquid of topical application for wounds. (Machine-translation by Google Translate, not legally binding)
WO2010076730A1 (en) * 2009-01-02 2010-07-08 Donald, Jenny Method for the treatment of an hiv infection
WO2011001208A1 (en) * 2009-06-29 2011-01-06 Csir The use of an extract of helichrysum, for the treatment of hiv/aids
WO2011104489A2 (en) * 2010-02-26 2011-09-01 L'oreal Use of essential oil of oregano or of rosewood, or constituents thereof, in the cosmetic treatment of keratoses
WO2011104490A2 (en) * 2010-02-26 2011-09-01 L'oreal Use of essential oil of oregano and of rosewood, or constituents thereof, in the therapeutic treatment of keratoses
US20110293757A1 (en) * 2008-07-18 2011-12-01 Novasel Australia Pty. Ltd. Compositions Comprising Tea Tree Oil and Methods for the Prevention and Treatment of Cancer
US8147878B2 (en) 2006-01-17 2012-04-03 Aboca S.P.A. Societa' Agricola Water insoluble helychrisum extract, process for preparing the same and uses thereof
WO2013164442A1 (en) * 2012-05-04 2013-11-07 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Plant extract for the treatment of an hiv infection as well as products relating thereto
RU2704038C1 (en) * 2018-04-25 2019-10-23 Светлана Александровна Чубатова Basic composition for preparation of biologically active means of human environment treatment
CN112220891A (en) * 2019-06-26 2021-01-15 株式会社Sd生命工学 Antibacterial and antifungal composition containing herbal mixed essential oil as effective component

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2709964A1 (en) * 1993-09-14 1995-03-24 Dupont Paul Antiviral pharmaceutical compositions proposed in the treatment of AIDS and herpes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2709964A1 (en) * 1993-09-14 1995-03-24 Dupont Paul Antiviral pharmaceutical compositions proposed in the treatment of AIDS and herpes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARCHIVES DE L'INSTITUT PASTEUR DE MADAGASCAR, vol. 56, no. 1, 1989, pages 261 - 272, ISSN: 0020-2495 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1989, RAHARIVELOMANANA P J ET AL: "CONTRIBUTION TO THE STUDY OF THE ANTIMICROBIAL ACTION OF SOME ESSENTIAL OILS EXTRACTED FROM PLANTS OF MADAGASCAR II. LAURACEAE", XP002203138, Database accession no. PREV199090078851 *
MEDICI DE D ET AL: "Chemical analysis of essential oils of Malagasy medicinal plants by gas chromatography and NMR spectroscopy", BIOSIS, XP002168060 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006087039A1 (en) * 2005-02-17 2006-08-24 Propharex Sa Broad spectrum anti viral herbal composition
US8147878B2 (en) 2006-01-17 2012-04-03 Aboca S.P.A. Societa' Agricola Water insoluble helychrisum extract, process for preparing the same and uses thereof
WO2007116062A1 (en) * 2006-04-11 2007-10-18 Swiss Caps Rechte Und Lizenzen Ag Capsules containing plant preparations
CH699154B1 (en) * 2006-04-11 2010-01-29 Swiss Caps Rechte & Lizenzen Capsule containing plant preparations.
ES2340352A1 (en) * 2008-06-06 2010-06-01 Pedro Enrique Alonso Hernandez Unguent or liquid of topical application for wounds. (Machine-translation by Google Translate, not legally binding)
US20110293757A1 (en) * 2008-07-18 2011-12-01 Novasel Australia Pty. Ltd. Compositions Comprising Tea Tree Oil and Methods for the Prevention and Treatment of Cancer
WO2010076730A1 (en) * 2009-01-02 2010-07-08 Donald, Jenny Method for the treatment of an hiv infection
WO2011001208A1 (en) * 2009-06-29 2011-01-06 Csir The use of an extract of helichrysum, for the treatment of hiv/aids
US9919019B2 (en) 2010-02-26 2018-03-20 L'oreal Use of essential oil of oregano or of rosewood, or constituents thereof, in the cosmetic treatment of keratoses
FR2956814A1 (en) * 2010-02-26 2011-09-02 Oreal USE OF ESSENTIAL OIL OF ORIGAN OR ROSE WOOD, OR THEIR CONSTITUENTS, IN THE COSMETIC TREATMENT OF KERATOSES
WO2011104490A2 (en) * 2010-02-26 2011-09-01 L'oreal Use of essential oil of oregano and of rosewood, or constituents thereof, in the therapeutic treatment of keratoses
WO2011104489A3 (en) * 2010-02-26 2012-03-22 L'oreal Use of essential oil of oregano or of rosewood in the treatment of actinic keratoses
WO2011104490A3 (en) * 2010-02-26 2012-03-22 L'oreal Use of essential oil of oregano or of rosewood for the treatment of cancerous keratoses
WO2011104489A2 (en) * 2010-02-26 2011-09-01 L'oreal Use of essential oil of oregano or of rosewood, or constituents thereof, in the cosmetic treatment of keratoses
FR2956817A1 (en) * 2010-02-26 2011-09-02 Oreal USE OF ESSENTIAL OIL OF ORIGAN OR ROSE WOOD, OR THEIR CONSTITUENTS, IN THE THERAPEUTIC TREATMENT OF KERATOSES
US9040103B2 (en) 2010-02-26 2015-05-26 L'oreal Use of essential oil of oregano and of rosewood, or constituents thereof, in the therapeutic treatment of keratoses
WO2013164442A1 (en) * 2012-05-04 2013-11-07 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Plant extract for the treatment of an hiv infection as well as products relating thereto
RU2704038C1 (en) * 2018-04-25 2019-10-23 Светлана Александровна Чубатова Basic composition for preparation of biologically active means of human environment treatment
WO2019209136A1 (en) * 2018-04-25 2019-10-31 Chubatova Svetlana Alexandrovna Basic composition for producing a biologically active agent
CN112105372A (en) * 2018-04-25 2020-12-18 S·A·丘巴托娃 Base composition for the production of bioactive agents
JP2021522339A (en) * 2018-04-25 2021-08-30 チュバトヴァ スヴェトラーナ アレキサンドロヴナCHUBATOVA, Svetlana Alexandrovna Basic composition for the production of biologically active agents
CN112220891A (en) * 2019-06-26 2021-01-15 株式会社Sd生命工学 Antibacterial and antifungal composition containing herbal mixed essential oil as effective component

Also Published As

Publication number Publication date
FR2830198B1 (en) 2004-10-15

Similar Documents

Publication Publication Date Title
Lawless The Encyclopedia of essential oils: the complete guide to the use of aromatic oils in aromatherapy, herbalism, health, and well being
EP0870507A1 (en) Synergistic herbal extracts
JP2005533767A (en) Terpene base material composition, preparation method thereof, and atmospheric spraying method
FR2830198A1 (en) Compositions containing Ravensara aromatica essential oil and one or more other essential oils for treatment of viral, fungal, and parasitic infections, cystic fibrosis, AIDS, and certain tumors
US8268367B2 (en) Topical herbal formulation for treatment of acne and skin disorders
US20110150995A1 (en) Solid Dosage Forms of Essential Oils
US8535737B2 (en) Composition with extracts from olive leaf, yarrow and rosemary for treating human diseases and conditions
US5948414A (en) Herbal based nasal spray
CA2763458A1 (en) Topical micro-emulsions for the treatment of rheumatic disorders
FR2504551A1 (en) Compsn. for treating skin, e.g. burns, eczema or acne - contains essential oils from Labiatae and other plant families
US8821948B2 (en) Therapeutic, bio-affecting and body treating composition
Stiles The essential oils complete reference guide: Over 250 recipes for natural wholesome aromatherapy
JP6847656B2 (en) Topical composition
US20100143508A1 (en) Limonene and yucca medical compound for treating human diseases and conditions
EP3337487B1 (en) Honokiol and magnolol formulations with increased stability and improved uptake, and methods of use thereof
EP1049480B1 (en) Herbal anti-viral agent
JP2002241310A (en) Locally applying composition
MX2012008419A (en) Improved composition based on terpenoids and chloretone, and the use thereof in nasal items.
JPH09502455A (en) Immune-enhancing nutritional supplement
WO2017206014A1 (en) Long-acting mosquito repellent containing extracts of traditional chinese medicines
WO2022097042A1 (en) Novel therapeutic composition based on essential oils at low doses
US229874A (en) Christian dengel
CN1190190C (en) Antiviral and antibacterial cantharidinic anhydride medicine composition and its prepn process
JP2021050246A (en) External composition
WO2016044903A1 (en) Chemical compositions for the elaboration of an organic antimicrobial spray

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140530